Advertisement

Chronic HBV Infection: Interferon Therapy and Long-Term Outcomes

  • Tarik AsselahEmail author
  • Patrick Marcellin
Chapter

Abstract

Chronic hepatitis B infection affects around 240 million people worldwide, with long-term morbidity such as cirrhosis and hepatocellular carcinoma. Interferon treatment enhanced HBsAg seroclearance. Pegylated interferon induced a 10-15% yearly rate of HBsAg seroclearance in patients who developed sustained virological response in clinical trials. By contrast, treatment with nucleos (t) ides analogues did not significantly affect the rate of HBsAg seroclearance, especially in patients with hepatitis B e antigen (HBeAg) - negative disease. Recently, it has been shown that a significantly greater proportion of patients receiving tenofovir plus pegylated-interferon for 48 weeks had HBsAg loss than those receiving tenofovir or pegylated-interferon alone. HBsAg clearance is the closest to cure outcome, and there is increasing interest in HBsAg quantification. Quantification of serum HBsAg has also been recently shown to be a promising tool for monitoring virologic response in HBeAg-negative patients treated with pegylated interferon. This chapter reviews Interferon therapy and long-term outcomes.

Keywords

HBV cure Immune therapy cccDNA HBs quantification 

Abbreviations

AE

Adverse event

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

cccDNA

Covalently closed circular DNA

CHB

Chronic hepatitis B

ETV

Entecavir

HBeAg

HBe antigen

HBsAg

Hepatitis B surface antigen

HBV

Hepatitis B virus

IFN

Interferon

NAs

Nucleos(t)ide analogues

NI

Nucleoside inhibitors

NNI

Non-nucleoside inhibitors

PEG-IFN

Pegylated interferon

QD

Once daily

TDF

Tenofovir

Notes

Conflicts of Interest

Tarik Asselah is a speaker and investigator for BMS, Boehringer Ingelheim, Tibotec, Janssen, Gilead, Roche, and MSD.

Patrick Marcellin is a speaker and investigator for BMS, Boehringer Ingelheim, Tibotec, Janssen, Gilead, Roche, and MSD.

References

  1. Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Sci Rep. 2016;6:34935.  https://doi.org/10.1038/srep34935.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol. 2014;61(2):193–5.CrossRefPubMedGoogle Scholar
  3. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007;56:699–705.CrossRefPubMedGoogle Scholar
  4. Brunetto MR, Moriconi F, Bononi F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141–50.CrossRefPubMedGoogle Scholar
  5. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alfa-2b. Gastroenterology. 2008;135:459–67.CrossRefPubMedGoogle Scholar
  6. Chan HL, Wong VW, Chim AM, et al. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323–15.CrossRefPubMedGoogle Scholar
  7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRefGoogle Scholar
  8. Flink HJ, van Zonneveld M, Hansen BE, et al., HBV99-01study group. Treatment with Peg-interferon alpha-2b for HBe-Ag positive chronic hepatitis B: HBs loss is associated with genotype. Am J Gastroenterol. 2006;101:297–303.Google Scholar
  9. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, Dev A, Bell S, Pianko S, Chen R, Visvanathan K, Hammond R, Iser D, Rusli F, Sievert W, Desmond PV, Bowden DS, Thompson AJ. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol. 2013;28(5):861–6.CrossRefPubMedGoogle Scholar
  10. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–8.CrossRefPubMedGoogle Scholar
  11. Lampertico P, Viganò M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, Soffredini R, Abrignani S, De Francesco R, Colombo M. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013;57(3):890–6.CrossRefPubMedGoogle Scholar
  12. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–95.CrossRefPubMedGoogle Scholar
  13. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.CrossRefPubMedGoogle Scholar
  14. Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol. 2013;28:912–23.CrossRefPubMedGoogle Scholar
  15. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36(5 Suppl 1):S47–56.PubMedGoogle Scholar
  16. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med. 2004;351:1206–17.CrossRefPubMedGoogle Scholar
  17. Marcellin P, Bonino F, Lau GK, et al. Peginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136:2169–79.CrossRefPubMedGoogle Scholar
  18. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013a;318:468–75.CrossRefGoogle Scholar
  19. Marcellin P, Bonino F, Yurdayin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013b;7:88–97.CrossRefPubMedGoogle Scholar
  20. Marcellin P, Martinot-Peignoux M, Asselah T, Batrla R, Messinger D, Rothe V, Lau G, Liaw YF. Serum levels of hepatitis B surface antigen predict severity of fibrosis in patients with E antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol. 2015;13(8):1532–9.e1.CrossRefPubMedGoogle Scholar
  21. Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134–44.CrossRefPubMedGoogle Scholar
  22. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naıve, e antigen-positive patients. J Hepatol. 2013;58:1089–95.CrossRefPubMedGoogle Scholar
  23. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34(Suppl. 1):97–107.CrossRefPubMedGoogle Scholar
  24. Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int. 2015;35(Suppl):82–90.CrossRefPubMedGoogle Scholar
  25. Martinot-Peignoux M, Lapalus M, Maylin S, Boyer N, Castelnau C, Giuily N, Pouteau M, Moucari R, Asselah T, Marcellin P. Baseline HBsAg and HBcrAg titres allow peginterferon-based ‘precision medicine’ in HBeAg-negative chronic hepatitis B patients. J Viral Hepat. 2016;23(11):905–11.CrossRefPubMedGoogle Scholar
  26. Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009a;50(6):1084–92.CrossRefPubMedGoogle Scholar
  27. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009b;49:1151–7.CrossRefPubMedGoogle Scholar
  28. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.CrossRefPubMedGoogle Scholar
  29. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.CrossRefPubMedGoogle Scholar
  30. Wiegand J, Hasenclever D, Tillmann H. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13:211–20.PubMedGoogle Scholar
  31. World Health Organization. Hepatitis B Fact sheet No. 204. 2012 [Cited 2012 Oct 24]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/
  32. Wu HL, Hsiao TH, Chen PJ, Wong SH, Kao JH, Chen DS, Lu JY, Lu TP, Chen Y, Chuang EY, Tu HC, Liu CJ. Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients. Sci Rep. 2016;6:31349.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Zhang Q, Lapalus M, Asselah T, Laouénan C, Moucari R, Martinot-Peignoux M, Bieche I, Estrabaud E, De Muynck S, Boyer N, Bedossa P, Vidaud M, Marcellin P, Lada O. IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients. J Viral Hepat. 2014;21(7):525–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.UMR1149, Team “Physiopathologie et traitements des hépatites virales”Centre de Recherche sur l’InflammationParisFrance
  2. 2.Hepatology Department, Beaujon HospitalUniversité Denis Diderot Paris 7ClichyFrance

Personalised recommendations